Bio Medica Laboratories Limited
NNSE:BMLL155.00
INR
-0.50
(-0.32%)
ISIN
INE1BKA01015
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Pradeep Mehta
- Full Time Employees
- 58
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Indore India
- IPO Date
- May 29, 2026
- Website
- biomedica.co.in
- Similar Companies
- Business
- Bio Medica Laboratories Limited is an India-based pharmaceutical manufacturing company that specializes in the development, production, and contract manufacturing of parenteral formulations for human and veterinary healthcare applications. Founded in 2015 and headquartered in Indore, Madhya Pradesh, India, the company operates primarily through a business-to-business (B2B) model, serving domestic and institutional pharmaceutical marketing enterprises. The company offers a comprehensive portfolio of generic and ethical injectable products and related services, including small-volume liquid injections supplied in ampoules and glass vials; sterile dry powder injections; cephalosporin and beta-lactam antibiotic parenterals; veterinary injectable solutions and suspensions; over-the-counter and prescription formulations; customized third-party contract manufacturing; analytical quality control; and Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) compliant formulation support. Bio Medica Laboratories Limited conducts its operational and manufacturing activities across dedicated production facilities situated in the Sanwer Road Industrial Area of Indore, India. In recent corporate developments, the company converted from a private limited company to a public limited entity and adopted its current name in October 2024; completed an initial public offering (IPO) on the NSE Emerge platform in May 2026 raising approximately INR 52.43 crore; and commenced expansion projects to establish a new sterile manufacturing unit at its existing Indore facility to scale production capacity and enhance its formulation capabilities.